Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Undifferentiated pleomorphic sarcoma (UPS), drawn from the whole corpus: 3 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No molecular driver to target; the diagnosis is defined by what the tumour is not.
A third of high-grade limb tumours still metastasise to the lungs.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Atlas of advanced disease · How cancer spreads: the metastasis stages.
Which patients gain from neoadjuvant chemotherapy versus immunotherapy is not settled.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 10 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
Standard arm DFS HR ~0.
Pembrolizumab produced objective responses mainly in undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma, with little activity in bone sarcomas.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.